Biomark Diagnostics (Biomark Diagnostics) Long-Term Capital Lease Obligation

: $0.41 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Biomark Diagnostics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.41 Mil.

Biomark Diagnostics's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($0.14 Mil) to Sep. 2023 ($0.11 Mil) but then increased from Sep. 2023 ($0.11 Mil) to Dec. 2023 ($0.41 Mil).

Biomark Diagnostics's annual Long-Term Capital Lease Obligation increased from Mar. 2021 ($0.01 Mil) to Mar. 2022 ($0.40 Mil) but then declined from Mar. 2022 ($0.40 Mil) to Mar. 2023 ($0.16 Mil).

Biomark Diagnostics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Biomark Diagnostics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.01

0.40

0.16

Biomark Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.19	0.16	0.14	0.11	0.41

Biomark Diagnostics (OTCPK:BMKDF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Biomark Diagnostics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics (Biomark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

BUX:Canada

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines